Continuous infusion mitoxantrone in relapsed acute nonlymphocytic leukemia

Area of Science:

• Oncology
• Pharmacology
• Hematology

Background:

• Mitoxantrone is an anthraquinone derivative with demonstrated activity against acute leukemia.
• Maintaining consistent cytotoxic drug levels is crucial for effective cancer therapy.
• Previous administration methods may not have optimized steady-state concentrations.

Purpose of the Study:

• To evaluate continuous infusion mitoxantrone for maintaining cytotoxic steady-state levels.
• To assess the efficacy and toxicity of this delivery method in acute leukemia patients.
• To determine the relationship between drug levels, toxicity, and clinical response.

Main Methods:

• Patients received continuous infusion mitoxantrone.
• Plasma drug levels were monitored daily to determine steady-state concentrations and clearance.
• Leukemia cell mass reduction was assessed, with some patients receiving additional etoposide.
• Toxicity profiles, including myelosuppression, mucositis, and hepatic dysfunction, were recorded.

Main Results:

• Mean steady-state plasma mitoxantrone level was 16.8 ng/ml, with no observed drug accumulation.
• Drug levels were undetectable 24 hours post-infusion.
• Over 90% reduction in leukemia cell mass was observed by day 6 in all patients.
• Four patients (36%) achieved complete remission; one had a bone marrow remission with persistent granulocytic sarcoma.
• Toxicities were severe but tolerable; no correlation was found between drug levels and response or toxicity.

Conclusions:

• Continuous infusion of mitoxantrone achieves cytotoxic plasma levels and effectively reduces acute nonlymphocytic leukemia (ANLL) cell mass.
• The observed toxicity profile was manageable, suggesting potential for dose escalation.
• This administration method warrants further investigation for optimizing acute leukemia treatment.